Invizius is a clinical-stage biotechnology company focused on developing advanced complement therapies aimed at treating inflammatory, fibrotic, and autoimmune disorders. Their proprietary technology leverages natural complement regulators to enhance patient safety and clinical efficacy. The company's lead product, H-Guard, is currently in clinical development and is designed to address significant unmet medical needs for patients undergoing dialysis and other extracorporeal circuit therapies. H-Guard functions as a priming solution that is added to existing priming fluids, utilizing a potent down-regulator of the innate immune system, specifically targeting excessive complement activation that can occur during these medical procedures.

The foundation of Invizius's technology is based on the research of the pneumococcal surface protein C (PspCN), which is derived from the pathogenic bacterium Streptococcus pneumoniae. This protein binds to the human complement down-regulator Factor H, enhancing its effectiveness in regulating the complement system. By mimicking the body's own mechanisms to evade immune responses, PspCN-based therapies aim to restore balance in the complement system, potentially offering a safer and more effective alternative to first-generation complement therapies that often come with significant side effects. The innovative approach of Invizius not only seeks to mitigate the risks associated with excessive complement activation but also aims to improve patient outcomes in various clinical settings.

United Kingdom

Invizius is a spin-out based on world-class research carried out at the University of Edinburgh, Scotland.  Invizius is developing Second Generation Complement Therapeutics to significantly improve the clinical outcomes of patients  with Acute Kidney Injury  receiving CRRT and patient on Renal replacement Therapy receiving Peritoneal Dialysis.

Despite significant improvements in haemodialysis membranes Complement activation by contact with a foreign surface remains a serious issue with short, medium and long term clinical implications. Complement activation has also been associated with Peritoneal Dialysis(PD) and may be a driver of fibrotic changes that limit PD duration.

 



Invizius

Company Details